Roche on Monday said its Foundation Medicine unit won US Food and Drug Administration (FDA) approval for a test to help doctors understand the genetic profile of patients' tumours and guide them to effective therapies.

Roche, which owns 58% of Foundation, is hoping to use the FoundationOne CDx assay to personalise cancer care, where treatment is better tailored to the specific molecular characteristics of each patient's disease.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.